Lavie Bio
Microbiome-based Products for Improved Food Quality
Company Overview
Snapshot
Founded in January 2019, Lavie Bio operates with 11–50 employees and has raised a total of $37M across three funding rounds from two investors. The company was acquired by ICL in April 2025.
Business overview
Lavie Bio is an Agriculture & Food Technologies company focused on enhancing food quality, health, and agricultural sustainability through microbiome-based agricultural biological products. The company develops biostimulants and biopesticides using proprietary computational predictive technologies, with a specific focus on corn biostimulants through an ongoing collaboration with Corteva. Lavie Bio operates within the Ag Tech sector, serving the agriculture and food industries, particularly in crop treatment and genetics.
Strategic signal
In September 2024, Lavie Bio received a grant from the Israel Innovation Authority to advance its 'MicroFermentor' technology. This grant signals validation for Lavie Bio's innovative approach to making ag-biologicals more economically viable, which could significantly impact the sustainable farming and agricultural input markets by enabling broader adoption of microbiome-based solutions.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent development for Lavie Bio?
- In April 2025, Lavie Bio was acquired by ICL, marking a major exit for the company and integrating its microbiome-based agricultural solutions into a larger corporate structure.
- Did Lavie Bio receive any grants recently?
- In September 2024, Lavie Bio received a grant from the Israel Innovation Authority to further the development of its 'MicroFermentor' technology, aimed at improving the economics of ag-biologicals.
- What was a key partnership for Lavie Bio in 2024?
- In February 2024, Lavie Bio announced a partnership with Syngenta to discover and develop novel bio-insecticides, expanding its product pipeline in biological crop protection.
- What was a recent financial milestone for Lavie Bio related to its licensing agreements?
- In February 2024, Lavie Bio successfully secured a second half advance payment of $2.5M after meeting the licensing agreement requirements with Corteva.
- When did Lavie Bio establish a strategic collaboration with ICL?
- In August 2022, ICL and Lavie Bio entered into a strategic collaboration to develop novel bio-stimulant products, which included an investment from.